Development of siRNA payloads to target KRAS-mutant cancer.

UNLABELLED RNAi is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must combine potent siRNA payloads with reliable in vivo delivery for efficient target inhibition. We used a functional "Sensor" assay to establish a library of potent siRNAs against RAS pathway genes and to show that they efficiently suppress their targets at low dose. This reduces off-target effects and enables combination gene knockdown. We administered Sensor siRNAs in vitro and in vivo and validated the delivery of KRAS siRNA alone and siRNA targeting the complete RAF effector node (A/B/CRAF) as promising strategies to treat KRAS-mutant colorectal cancer. We further demonstrate that improved therapeutic efficacy is achieved by formulating siRNA payloads that combine both single-gene siRNA and node-targeted siRNAs (KRAS + PIK3CA/B). The customizable nature of Sensor siRNA payloads offers a universal platform for the combination target identification and development of RNAi therapeutics. SIGNIFICANCE To advance RNAi therapy for KRAS-mutant cancer, we developed a validated siRNA library against RAS pathway genes that enables combination gene silencing. Using an in vivo model for real-time siRNA delivery tracking, we show that siRNA-mediated inhibition of KRAS as well as RAF or PI3K combinations can impair KRAS-mutant colorectal cancer in xenograft models.

[1]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[2]  S. Lowe,et al.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors , 2005, Nature Genetics.

[3]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[4]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[5]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[6]  D. Tuveson,et al.  C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.

[7]  P. Zamore,et al.  Kinetic analysis of the RNAi enzyme complex , 2004, Nature Structural &Molecular Biology.

[8]  G. Hannon.  RNA interference : RNA , 2002 .

[9]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[10]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[11]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[12]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[13]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Hainsworth,et al.  A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Christof Fellmann,et al.  Stable RNA interference rules for silencing , 2013, Nature Cell Biology.

[16]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[17]  Martin L. Miller,et al.  Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs , 2009, Nature Biotechnology.

[18]  M. Barbacid,et al.  Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival , 2010, The EMBO journal.

[19]  Eric B Haura,et al.  A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[20]  B. Spencer‐Dene,et al.  Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance , 2013, Cancer cell.

[21]  Ferdinando Di Cunto,et al.  Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs , 2011, Cell.

[22]  Michael J. Emanuele,et al.  Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells , 2012, Proceedings of the National Academy of Sciences.

[23]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[24]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[25]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[26]  Mark E. Davis.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[27]  J. Burnett,et al.  Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges , 2013, Pharmaceuticals.

[28]  F. McCormick,et al.  Therapeutic strategies for targeting ras proteins. , 2011, Genes & cancer.

[29]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[30]  B. Spencer‐Dene,et al.  Requirement for Interaction of PI3-Kinase p110 alpha with RAS in Lung Tumor Maintenance , 2013 .

[31]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[32]  S. Elledge,et al.  Functional identification of optimized RNAi triggers using a massively parallel sensor assay. , 2011, Molecular cell.

[33]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[34]  Jean-Philippe Vert,et al.  An accurate and interpretable model for siRNA efficacy prediction , 2006, BMC Bioinformatics.

[35]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[36]  F. McCormick,et al.  RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. , 2013, Cancer cell.

[37]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[38]  D. Morrison,et al.  Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. , 2013, Molecular cell.

[39]  Mishal N. Patel,et al.  Objective assessment of cancer genes for drug discovery , 2012, Nature Reviews Drug Discovery.

[40]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[41]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.